NCT04844931: RIP-HIGH

Remote Ischemic Conditioning With Local Ischemic Postconditioning in High-Risk ST-elevation Myocardial Infarction

Active, enrolled NA Last updated 13 March 2025

What this trial tests

NA trial testing RIC + PostC + Standard PCI in ST Elevation Myocardial Infarction in 250 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

5 July 2021

Primary endpoint
31 December 2025

1 July 2030

Quick facts

Lead sponsor	Helios Health Institute GmbH
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	250
Start date	5 July 2021
Primary completion	31 December 2025
Estimated completion	1 July 2030
Sites	11 locations across Austria, Germany

Drugs / interventions tested

• RIC + PostC + Standard PCI
• Standard PCI

Conditions studied

• ST Elevation Myocardial Infarction — all drugs for ST Elevation Myocardial Infarction →

Sponsor

Helios Health Institute GmbH

Who can join

18 and older, any sex, with ST Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The RIP-HIGH trial is a two-arm randomized controlled trial aiming to compare the impact of combined remote ischemic conditioning (RIP) and local ischemic postconditioning (PostC) vs. standard of care on clinical outcome in high-risk ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection.
   Heusch G, Andreadou I, Bell R, Bertero E, et al · · 2023 · cited 80× · PMID 37839355 · DOI 10.1016/j.redox.2023.102894
2. Remote ischaemic conditioning: defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop.
   Bell RM, Basalay M, Bøtker HE, Beikoghli Kalkhoran S, et al · · 2022 · cited 40× · PMID 35970954 · DOI 10.1007/s00395-022-00947-2
3. Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy.
   Francis R, Chong J, Ramlall M, Bucciarelli-Ducci C, et al · · 2021 · cited 16× · PMID 34648075 · DOI 10.1007/s00395-021-00896-2
4. Reperfusion Injury: How Can We Reduce It by Pre-, Per-, and Postconditioning.
   Buske M, Desch S, Heusch G, Rassaf T, et al · · 2023 · cited 11× · PMID 38202166 · DOI 10.3390/jcm13010159
5. Temporal Trends in Infarct Severity Outcomes in ST-Segment-Elevation Myocardial Infarction: A Cardiac Magnetic Resonance Imaging Study.
   Lechner I, Reindl M, Tiller C, Holzknecht M, et al · · 2023 · cited 11× · PMID 37489726 · DOI 10.1161/jaha.122.028932
6. Reperfused Myocardial Infarction: The Road to CCS Classification of Acute MI and Beyond.
   Dharmakumar R, Kloner RA, Fishbein M, Heusch G, et al · · 2025 · cited 10× · PMID 40021272 · DOI 10.1016/j.jacadv.2024.101528
7. Inter-organ communication: pathways and targets to cardioprotection and neuro-protection. A report from the 12th Hatter Cardiovascular Institute workshop.
   Pearce L, Galán-Arriola C, Bell RM, Carr RD, et al · · 2025 · cited 7× · PMID 39681732 · DOI 10.1007/s00395-024-01094-6
8. Is There a Mitochondrial Protection via Remote Ischemic Conditioning in Settings of Anticancer Therapy Cardiotoxicity?
   Kleinbongard P, Andreadou I. · · 2024 · cited 6× · PMID 38512567 · DOI 10.1007/s11897-024-00658-w